These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 25393253)

  • 41. Increased megakaryocytic proliferation, pro-platelet deposition and expression of fibrosis-associated factors in children with chronic myeloid leukaemia with bone marrow fibrosis.
    Hussein K; Stucki-Koch A; Göhring G; Kreipe H; Suttorp M
    Leukemia; 2017 Jul; 31(7):1540-1546. PubMed ID: 28239144
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cells from chronic myelogenous leukaemia patients at presentation exhibit multidrug resistance not mediated by either MDR1 or MRP1.
    Carter A; Dann EJ; Katz T; Shechter Y; Oliven A; Regev R; Eytan E; Rowe JM; Eytan GD
    Br J Haematol; 2001 Sep; 114(3):581-90. PubMed ID: 11552983
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The Bone Marrow Immune Microenvironment in CML: Treatment Responses, Treatment-Free Remission, and Therapeutic Vulnerabilities.
    Patterson SD; Copland M
    Curr Hematol Malig Rep; 2023 Apr; 18(2):19-32. PubMed ID: 36780103
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Stromal cell derived factor-1 (CXCL12) chemokine gene variant in myeloid leukemias.
    El-Ghany HM; El-Saadany ZA; Bahaa NM; Ibrahim NY; Hussien SM
    Clin Lab; 2014; 60(5):735-41. PubMed ID: 24839815
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Identification of CXCL12-abundant reticular cells in human adult bone marrow.
    Aoki K; Kurashige M; Ichii M; Higaki K; Sugiyama T; Kaito T; Ando W; Sugano N; Sakai T; Shibayama H; ; Takaori-Kondo A; Morii E; Kanakura Y; Nagasawa T
    Br J Haematol; 2021 May; 193(3):659-668. PubMed ID: 33837967
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Epigenetic regulation of cathepsin L expression in chronic myeloid leukaemia.
    Samaiya M; Bakhshi S; Shukla AA; Kumar L; Chauhan SS
    J Cell Mol Med; 2011 Oct; 15(10):2189-99. PubMed ID: 21496199
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Assessment of the Number and Phenotype of Macrophages in the Human BMB Samples of CML.
    Song JX; Dian ZJ; Wen Y; Mei F; Li RW; Sa YL
    Biomed Res Int; 2016; 2016():8086398. PubMed ID: 27999815
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Up-regulated expression of CXCL12 in human spleens with extramedullary haematopoiesis.
    Miwa Y; Hayashi T; Suzuki S; Abe S; Onishi I; Kirimura S; Kitagawa M; Kurata M
    Pathology; 2013 Jun; 45(4):408-16. PubMed ID: 23619587
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Wogonin reverses the drug resistance of chronic myelogenous leukemia cells to imatinib through CXCL12-CXCR4/7 axis in bone marrow microenvironment.
    Cao H; Gao Y; Wang R; Guo Q; Hui H
    Ann Transl Med; 2020 Sep; 8(17):1046. PubMed ID: 33145265
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Collagenase activity and collagenase-inhibitory factors of serum and bone marrow fibroblast-conditioned medium in chronic myelogenous leukaemia.
    Yonekura S; Nagao T
    Br J Haematol; 1994 Feb; 86(2):308-15. PubMed ID: 7515266
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Morphology, Morphometry, and Immunohistochemical Profile of Megakaryocytes and Bone Marrow Microenvironment in Disease Progression and Therapy Resistance in Chronic Myeloid Leukemia.
    Kana S; Basu D; Kar R; Nachiappa Ganesh R; Dubashi B; Kt H
    Cureus; 2024 Aug; 16(8):e67772. PubMed ID: 39328663
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Increase of T and B cells and altered BACH2 expression patterns in bone marrow trephines of imatinib-treated patients with chronic myelogenous leukaemia.
    Von Laffert M; Hänel M; Dietel M; Anagnostopoulos I; Jöhrens K
    Oncol Lett; 2016 Oct; 12(4):2421-2428. PubMed ID: 27698808
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Oroxylin a Inhibits the Protection of Bone Marrow Microenvironment on CML Cells Through CXCL12/CXCR4/P-gp Signaling Pathway.
    Cao H; Li W; Zhou Y; Tan R; Yang Y; Zhou Y; Guo Q; Zhao L
    Front Oncol; 2019; 9():188. PubMed ID: 31024831
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Up-regulation of CXCL8/interleukin-8 production in response to CXCL12 in chronic lymphocytic leukemia.
    Perbellini O; Cioffi F; Malpeli G; Zanolin E; Lovato O; Scarpa A; Pizzolo G; Scupoli MT
    Leuk Lymphoma; 2015 Jun; 56(6):1897-900. PubMed ID: 25347424
    [No Abstract]   [Full Text] [Related]  

  • 55. Corrigendum: Oroxylin a Inhibits the Protection of Bone Marrow Microenvironment on CML Cells Through CXCL12/CXCR4/P-gp Signaling Pathway.
    Cao H; Li W; Zhou Y; Tan R; Yang Y; Zhou Y; Guo Q; Zhao L
    Front Oncol; 2019; 9():990. PubMed ID: 31608242
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Retraction: Oroxylin a Inhibits the Protection of Bone Marrow Microenvironment on CML Cells Through CXCL12/CXCR4/P-gp Signaling Pathway.
    Frontiers Editorial Office
    Front Oncol; 2020; 10():714. PubMed ID: 32373542
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy, safety, and lack of interactions with the use of raltegravir in HIV-infected patients undergoing antineoplastic chemotherapy.
    Bañón S; Machuca I; Araujo S; Moreno A; Perez-Elías MJ; Moreno S; Casado JL
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19590. PubMed ID: 25394095
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cost-effectiveness of the sequential application of tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.
    Rochau U; Sroczynski G; Wolf D; Schmidt S; Jahn B; Kluibenschaedl M; Conrads-Frank A; Stenehjem D; Brixner D; Radich J; Gastl G; Siebert U
    Leuk Lymphoma; 2015; 56(8):2315-25. PubMed ID: 25393806
    [TBL] [Abstract][Full Text] [Related]  

  • 59. OCT-1, ABCB1, and ABCG2 Expression in Imatinib-Resistant Chronic Myeloid Leukemia Treated with Dasatinib or Nilotinib.
    Kim YK; Lee SS; Jeong SH; Ahn JS; Yang DH; Lee JJ; Shin MG; Kim HJ
    Chonnam Med J; 2014 Dec; 50(3):102-11. PubMed ID: 25568846
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Evolution of chronic myeloid leukemia on nilotinib after failure of imatinib].
    Sawadogo S; Hien FM; Ouédraogo MS; Drabo YJ
    Pan Afr Med J; 2014; 18():142. PubMed ID: 25419280
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.